PIB-PET opens diagnostic front in Alzheimer's disease
Australian researchers using PET imaging with Pittsburgh Compound B found a link between the progressive accumulation of beta-amyloid plaque in the brain and mild cognitive impairment and Alzheimer's disease. Findings could pertain to anti-amyloid drugs now in clinical trials.
Australian researchers using PET imaging with Pittsburgh Compound B found a link between the progressive accumulation of beta-amyloid plaque in the brain and mild cognitive impairment and Alzheimer's disease. Findings could pertain to anti-amyloid drugs now in clinical trials.
Dr. Christopher C. Rowe, director of nuclear medicine at the Austin Hospital's Centre for PET in Melbourne, and colleagues evaluated 44 Alzheimer's patients, 44 patients with mild cognitive impairment, and 34 healthy controls. The trial correlated results from psychometric memory tests and PIB standard uptake values in the frontal, posterior cingulate, parietal, lateral temporal, and occipital brain regions. Researchers found cortical PIB binding in all Alzheimer's patients, 60% of subjects with measurable cognitive deficits, and 20% of healthy volunteers. Findings were presented at the 2007 SNM meeting.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
